Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. https://doi.org/10.3322/caac.21660
Jemal, A., Ward, E. M., Johnson, C. J., Cronin, K. A., Ma, J., Ryerson, B., et al. (2017). Annual report to the nation on the status of cancer, 1975–2014, Featuring Survival. JNCI: Journal of the National Cancer Institute, 109(9), https://doi.org/10.1093/jnci/djx030.
Villanueva, A. (2019). Hepatocellular Carcinoma. New England Journal of Medicine, 380(15), 1450–1462. https://doi.org/10.1056/NEJMra1713263
In der Stroth, L., Tharehalli, U., Gunes, C., & Lechel, A. (2020). Telomeres and telomerase in the development of liver cancer. Cancers (Basel), 12(8), https://doi.org/10.3390/cancers12082048.
Delire, B., & Starkel, P. (2015). The Ras/MAPK pathway and hepatocarcinoma: Pathogenesis and therapeutic implications. European Journal of Clinical Investigation, 45(6), 609–623. https://doi.org/10.1111/eci.12441
Chen, C., & Wang, G. (2015). Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy. World Journal of Hepatology, 7(15), 1964–1970. https://doi.org/10.4254/wjh.v7.i15.1964
Kudo, M. (2011). Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma. Digestive Diseases, 29(3), 289–302. https://doi.org/10.1159/000327562
Meyerson, M., Counter, C. M., Eaton, E. N., Ellisen, L. W., Steiner, P., Caddle, S. D., et al. (1997). hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell, 90(4), 785–795. https://doi.org/10.1016/s0092-8674(00)80538-3
Ramakrishna, G., Rastogi, A., Trehanpati, N., Sen, B., Khosla, R., & Sarin, S. K. (2013). From cirrhosis to hepatocellular carcinoma: New molecular insights on inflammation and cellular senescence. Liver Cancer, 2(3–4), 367–383. https://doi.org/10.1159/000343852
Wu, Y., Zhang, J., Zhang, H., & Zhai, Y. (2016). Hepatitis B virus X protein mediates yes-associated protein 1 upregulation in hepatocellular carcinoma. Oncology Letters, 12(3), 1971–1974. https://doi.org/10.3892/ol.2016.4885
Wang, Y., Han, C., Lu, L., Magliato, S., & Wu, T. (2013). Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology, 58(3), 995–1010. https://doi.org/10.1002/hep.26394
Chow, A. K., Yau, S. W., & Ng, L. (2020). Novel molecular targets in hepatocellular carcinoma. World Journal of Clinical Oncology, 11(8), 589–605. https://doi.org/10.5306/wjco.v11.i8.589
Singal, A. G., Lampertico, P., & Nahon, P. (2020). Epidemiology and surveillance for hepatocellular carcinoma: New trends. Journal of Hepatology, 72(2), 250–261. https://doi.org/10.1016/j.jhep.2019.08.025
McGlynn, K. A., Petrick, J. L., & El-Serag, H. B. (2021). Epidemiology of hepatocellular carcinoma. Hepatology, 73(Suppl 1), 4–13. https://doi.org/10.1002/hep.31288
Global Burden of Disease Liver Cancer, C, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., et al. (2017). The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the Global Burden of Disease Study 2015. JAMA Oncology, 3(12), 1683–1691. https://doi.org/10.1001/jamaoncol.2017.3055
Sangiovanni, A., Prati, G. M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., et al. (2006). The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology, 43(6), 1303–1310. https://doi.org/10.1002/hep.21176
Ioannou, G. N., Splan, M. F., Weiss, N. S., McDonald, G. B., Beretta, L., & Lee, S. P. (2007). Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol, 5(8), 938–945, 945 e931–934, https://doi.org/10.1016/j.cgh.2007.02.039.
Maucort-Boulch, D., de Martel, C., Franceschi, S., & Plummer, M. (2018). Fraction and incidence of liver cancer attributable to hepatitis B and C viruses worldwide. International Journal of Cancer, 142(12), 2471–2477. https://doi.org/10.1002/ijc.31280
Alfaiate, D., Clement, S., Gomes, D., Goossens, N., & Negro, F. (2020). Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Journal of Hepatology, 73(3), 533–539. https://doi.org/10.1016/j.jhep.2020.02.030
Beguelin, C., Moradpour, D., Sahli, R., Suter-Riniker, F., Luthi, A., Cavassini, M., et al. (2017). Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. Journal of Hepatology, 66(2), 297–303. https://doi.org/10.1016/j.jhep.2016.10.007
Chen, C. J., Wang, L. Y., Lu, S. N., Wu, M. H., You, S. L., Zhang, Y. J., et al. (1996). Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology, 24(1), 38–42. https://doi.org/10.1002/hep.510240108
Chu, Y. J., Yang, H. I., Wu, H. C., Liu, J., Wang, L. Y., Lu, S. N., et al. (2017). Aflatoxin B1 exposure increases the risk of cirrhosis and hepatocellular carcinoma in chronic hepatitis B virus carriers. International Journal of Cancer, 141(4), 711–720. https://doi.org/10.1002/ijc.30782
Chen, J., Zhu, J., Wang, G., Groopman, J. D., & Kensler, T. W. (2019). Qidong: a crucible for studies on liver cancer etiology and prevention. Cancer Biology and Medicine, 16(1), 24–37. https://doi.org/10.20892/j.issn.2095-3941.2018.0394
Yu, S. Z. (1995). Primary prevention of hepatocellular carcinoma. Journal of Gastroenterology and Hepatology, 10(6), 674–682. https://doi.org/10.1111/j.1440-1746.1995.tb01370.x
Mancebo, A., Gonzalez-Dieguez, M. L., Cadahia, V., Varela, M., Perez, R., Navascues, C. A., et al. (2013). Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups. Clinical Gastroenterology and Hepatology, 11(1), 95–101. https://doi.org/10.1016/j.cgh.2012.09.007
Trichopoulos, D., Bamia, C., Lagiou, P., Fedirko, V., Trepo, E., Jenab, M., et al. (2011). Hepatocellular carcinoma risk factors and disease burden in a European cohort: A nested case-control study. Journal of the National Cancer Institute, 103(22), 1686–1695. https://doi.org/10.1093/jnci/djr395
Chen, H. P., Shieh, J. J., Chang, C. C., Chen, T. T., Lin, J. T., Wu, M. S., et al. (2013). Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: Population-based and in vitro studies. Gut, 62(4), 606–615. https://doi.org/10.1136/gutjnl-2011-301708
Arase, Y., Kobayashi, M., Suzuki, F., Suzuki, Y., Kawamura, Y., Akuta, N., et al. (2013). Effect of type 2 diabetes on risk for malignancies includes hepatocellular carcinoma in chronic hepatitis C. Hepatology, 57(3), 964–973. https://doi.org/10.1002/hep.26087
Koh, J. C., Loo, W. M., Goh, K. L., Sugano, K., Chan, W. K., Chiu, W. Y., et al. (2016). Asian consensus on the relationship between obesity and gastrointestinal and liver diseases. Journal of Gastroenterology and Hepatology, 31(8), 1405–1413. https://doi.org/10.1111/jgh.13385
Seyda Seydel, G., Kucukoglu, O., Altinbasv, A., Demir, O. O., Yilmaz, S., Akkiz, H., et al. (2016). Economic growth leads to increase of obesity and associated hepatocellular carcinoma in developing countries. Annals of Hepatology, 15(5), 662–672. https://doi.org/10.5604/16652681.1212316
Atkins, J. L., Pilling, L. C., Masoli, J. A. H., Kuo, C. L., Shearman, J. D., Adams, P. C., et al. (2020). Association of Hemochromatosis HFE p. C282Y Homozygosity With Hepatic Malignancy. JAMA, 324(20), 2048–2057. https://doi.org/10.1001/jama.2020.21566
Elmberg, M., Hultcrantz, R., Ekbom, A., Brandt, L., Olsson, S., Olsson, R., et al. (2003). Cancer risk in patients with hereditary hemochromatosis and in their first-degree relatives. Gastroenterology, 125(6), 1733–1741. https://doi.org/10.1053/j.gastro.2003.09.035
Stewart, M. F. (2012). Review of hepatocellular cancer, hypertension and renal impairment as late complications of acute porphyria and recommendations for patient follow-up. Journal of Clinical Pathology, 65(11), 976–980. https://doi.org/10.1136/jclinpath-2012-200791
Linet, M. S., Gridley, G., Nyren, O., Mellemkjaer, L., Olsen, J. H., Keehn, S., et al. (1999). Primary liver cancer, other malignancies, and mortality risks following porphyria: A cohort study in Denmark and Sweden. American Journal of Epidemiology, 149(11), 1010–1015. https://doi.org/10.1093/oxfordjournals.aje.a009745
Baravelli, C. M., Sandberg, S., Aarsand, A. K., & Tollanes, M. C. (2019). Porphyria cutanea tarda increases risk of hepatocellular carcinoma and premature death: A nationwide cohort study. Orphanet Journal of Rare Diseases, 14(1), 77. https://doi.org/10.1186/s13023-019-1051-3
Cha, C., & Dematteo, R. P. (2005). Molecular mechanisms in hepatocellular carcinoma development. Best Practice and Research Clinical Gastroenterology, 19(1), 25–37. https://doi.org/10.1016/j.bpg.2004.11.005
Neuveut, C., Wei, Y., & Buendia, M. A. (2010). Mechanisms of HBV-related hepatocarcinogenesis. Journal of Hepatology, 52(4), 594–604. https://doi.org/10.1016/j.jhep.2009.10.033
Diaz, G., Engle, R. E., Tice, A., Melis, M., Montenegro, S., Rodriguez-Canales, J., et al. (2018). Molecular signature and mechanisms of hepatitis D virus-associated hepatocellular carcinoma. Molecular Cancer Research, 16(9), 1406–1419. https://doi.org/10.1158/1541-7786.MCR-18-0012
Nault, J. C., & Villanueva, A. (2015). Intratumor molecular and phenotypic diversity in hepatocellular carcinoma. Clinical Cancer Research, 21(8), 1786–1788. https://doi.org/10.1158/1078-0432.CCR-14-2602
Kawai-Kitahata, F., Asahina, Y., Tanaka, S., Kakinuma, S., Murakawa, M., Nitta, S., et al. (2016). Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. Journal of Gastroenterology, 51(5), 473–486. https://doi.org/10.1007/s00535-015-1126-4
Bruix, J., Han, K. H., Gores, G., Llovet, J. M., & Mazzaferro, V. (2015). Liver cancer: Approaching a personalized care. Journal of Hepatology, 62(1 Suppl), S144-156. https://doi.org/10.1016/j.jhep.2015.02.007
Guichard, C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., et al. (2012). Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature Genetics, 44(6), 694–698. https://doi.org/10.1038/ng.2256
Ahn, S. M., Jang, S. J., Shim, J. H., Kim, D., Hong, S. M., Sung, C. O., et al. (2014). Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification. Hepatology, 60(6), 1972–1982. https://doi.org/10.1002/hep.27198
留言 (0)